Cytokine Release Syndrome - Biotechnology

Relevant Publications

Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system.

Issue Release: 2024

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell Receptor/Anti-CD3 bispecific protein, in adults with Previously treated AML or NSCLC.

Issue Release: 2024

A multi-center real-life prospective study of axicabtagene ciloleucel versus tisagenlecleucel toxicity and outcomes in Large B-Cell Lymphomas.

Issue Release: 2024

Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.

Issue Release: 2024

Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.

Issue Release: 2024

Foxp3 Treg control allergic skin inflammation by restricting IFN-γ-driven neutrophilic infiltration and NETosis.

Issue Release: 2024

Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.

Issue Release: 2024

Heat shock protein 90α reduces CD8 T cell exhaustion in acute lung injury induced by lipopolysaccharide.

Issue Release: 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Issue Release: 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Issue Release: 2024

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.

Issue Release: 2024

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma.

Issue Release: 2024

IL-6 knockdown in a model of the human bone marrow, abrogates DNA damage induction in bystander cells post-chemotherapy induced cytokine release syndrome.

Issue Release: 2024

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.

Issue Release: 2024

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.

Issue Release: 2024

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology.

Issue Release: 2024

Immune-related adverse events of antibody-based biological medicines in cancer therapy.

Issue Release: 2024

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.

Issue Release: 2024

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma.

Issue Release: 2024

Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.

Issue Release: 2024

Why are Site Conditions Important?

What is the Future of Biotechnology Education?

What is AI in Agriculture?

What is Phytostabilization?

What Measures are Taken to Mitigate Risks?

What is Biostimulation?

What are Regulatory Frameworks?

What is the Role of Public Perception?

How are Biofuels Produced?

What Are the Future Prospects of Bioinformatics in Biotechnology?

Partnered Content Networks

Relevant Topics